NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

It's interesting, somewhere in the back of my memory banks (sometimes faulty), I remember having the discussion with AVII that the ACT IV Rindopepimut trial was initially advertised as gross total resection for the primary analysis, but then a funny thing happened, they later claim it was really minimum residual disease of less than 2cm. Hmm..... would the missing protocol straighten that out as well as the psPD inclusion issue???? Is there a charter as well? An SAP? Are sections missing?